OBJECTIVES Explore differences/similarities in epidemiology and drug treatment of metastatic breast cancer (MBC) in EU5. METHODS: All data was derived from the Kantar Health CancerMPact database, sources for which include country specific cancer registries, published scientific studies and proprietary physician surveys comprising 85 doctors seeing 9,255 patients per month.  Age and gender specific incidence rates, annual stage specific progression rates and annual stage specific survival rates are used to calculate total number of surviving patients at a specific stage up to 10 years after diagnosis. RESULTS: Prevalence of BC ranged  between 41-73 per 100K population across EU-5. Among BC patients, prevalence of MBC was similar:  8% (UK, Italy) to 10% (Germany, France, Spain). Overall 62% of MBC patients were diagnosed with HER2-negative disease (56% Germany-70% France). Among these patients 35-40% had active disease and were treated with chemotherapy. Patients with triple negative disease had had fewer lines of treatment than did not triple negative. Patients who are HER2-negative generally receive  between two and three lines of chemo therapy on average. Second line chemotherapy regimens varied.  Capecitabine was the most common therapy (mono and combination) in all countries ranging from 36% (UK) to 40% (Germany). 2^nd and 3^rdmost common therapies were vinorelbine (23%-26%) and paclitaxel (20%-23%) in Germany, Italy and Spain vs. docetaxel (18%-34%) and paclitaxel (11%-19%) in UK and France. In third line, the most commonly used agents were capecitabine (16%-44%) and vinorelbine (18%-26%). Eribulin was used in second line (3%-6%) and third line (11%-19%) in all countries except for Spain. CONCLUSIONS: Capecitabine is the most utilized chemotherapeutic agent in the second and third lines chemotherapy in Western Europe for HER2-negative patients. A variety of other regimens, primarily monotherapies, may also be used in later lines, including vinorelbine, gemcitabine, eribulin, and docetaxel.